Formycon - H119 results – FYB201 FDA filing imminent
Formycon's partner Bioeq IP (Bioeq) plans to file FYB201, a Lucentis biosimilar candidate, to treat neovascular age-related macular degeneration...
1k Views
Formycon - H118 results: FYB201 registration closer
Formycon has reported record H118 revenues, boosted by the one-off transfer of FYB202 into a joint venture with Aristo Pharma and payments stemming...
60 Views
Formycon - Lucentis biosimilar scores Phase III success
Formycon has announced that its Lucentis biosimilar FYB201 showed comparable efficacy with branded Lucentis in a global Phase III study in nAMD....
62 Views
H117 results show further business progress
In H117 Formycon disclosed that FYB202 is a proposed biosimilar of Stelara and it recently announced that it is in the process of entering into a...
77 Views
Building a pipeline of third-wave biosimilars
Formycon has reported FY16 financial results that highlight the progress of its biosimilars pipeline. During 2016 partner Bioeq IP AG started a...
79 Views